"Skin rashes" and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management

Immune checkpoint inhibitors have shown efficacy in the treatment of different cancers by stimulating the antitumoral activity of the patient's immune system, representing a major breakthrough in the field of cancer therapy. Monoclonal antibodies including anti-cytotoxic T-lymphocyte-associated...

Full description

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics Vol. 18; no. 3; p. 1889449
Main Authors: Sollena, Pietro, Cappilli, Simone, Federico, Francesco, Schinzari, Giovanni, Tortora, Giampaolo, Peris, Ketty
Format: Journal Article
Language:English
Published: United States Taylor & Francis 31.05.2022
Taylor & Francis Group
Subjects:
Advanced melanoma
Antibodies, Monoclonal - adverse effects
Antineoplastic Agents, Immunological - adverse effects
CTLA-4 Antigen - antagonists & inhibitors
CTLA-4 inhibitors
cutaneous adverse events
Exanthema - chemically induced
Humans
immune checkpoint inhibitors
Immunotherapy - adverse effects
Melanoma - drug therapy
Melanoma – Mini-Review
PD-1 inhibitors
skin rash
skin rash
cutaneous adverse events
PD-1 inhibitors
immune checkpoint inhibitors
Advanced melanoma
CTLA-4 inhibitors
ISSN:2164-5515, 2164-554X, 2164-554X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors have shown efficacy in the treatment of different cancers by stimulating the antitumoral activity of the patient's immune system, representing a major breakthrough in the field of cancer therapy. Monoclonal antibodies including anti-cytotoxic T-lymphocyte-associated protein 4, anti-programmed cell death protein 1 and its ligand inhibitors have been approved for advanced melanoma among other solid cancers. Although immunotherapy demonstrated a good safety profile, a new spectrum of multisystemic immune-related adverse events has been recently reported due to their use. Cutaneous reactions represent one of the leading adverse events, often reported in literature as "skin rash", and rarely further characterized in distinct dermatologic entities. Herein we describe the distinctive cutaneous rashes occurring during immunotherapies for advanced melanoma, discussing implications in the treatment management.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2164-5515
2164-554X
2164-554X
DOI:10.1080/21645515.2021.1889449